Endocrine Society GUIDELINES Bundle (free trial)

Obesity

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1140184

Contents of this Issue

Navigation

Page 7 of 11

Treatment Table 5. Pharmacotherapy for Obesity in the United States Mechanism of Action Drug Dose Mean Weight Loss with Placebo // with Drug Duration of Clinical Studies 5HT2c receptor agonist Lorcaserin • 10 mg bid -2.5% placebo // -5.8% 7.9 lb (3.6 kg ) a 1 year GABA receptor modulation (T) plus norepinephrine- releasing agent (P) Phentermine/topiramate (P/T) • 3.75 mg P/23 mg T ER qd (starting dose) • 7.5 mg P/46 mg T ER qd (recommended dose) • 15 mg P/92 mg T ER qd (high dose) -1.2% placebo // -7.8% (mid dose) -9.8% (full dose) 14.5 lb (recommended dose) (6.6%) a 18.9 lb (high dose) (8.6%) a 1 year GLP-1 agonist Liraglutide • 3.0 mg subcut qd -3% placebo // -7.4% (full dose) 12.8 lb (5.8 kg ) a 1 year Norepinephrine- releasing agent Phentermine resin b • Adipex-P (37.5 mg ) 37.5 mg/d • Ionamin (30 mg ) 30–37.5 mg qd - 4.5% placebo // -12% 7.9 lb (3.6 kg ) a 2–24 wks

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Obesity